Health system sits at the center of this dementia and brain health question.

Health system collaboration is advancing non-invasive Alzheimer’s therapy through a major partnership launched in March 2026 between Cognito Therapeutics and Ochsner Health. On March 25, 2026, these organizations announced the Brain Health Collaboratory, a coordinated effort designed to expand access to innovative, at-home Alzheimer’s treatments across the Gulf South region. Rather than waiting for yet another drug approval or treatment protocol, this initiative takes an existing promising technology—Spectris, a device that uses synchronized light and sound stimulation to promote healthy neural activity—and scales it across a real healthcare system spanning 47 hospitals and hundreds of care sites.

This approach represents a fundamental shift in how healthcare systems can bring emerging therapies to patients who need them now, particularly those in underserved communities. The collaboratory addresses a critical gap in Alzheimer’s care: most people living with cognitive decline don’t have access to the latest treatments, even when those treatments show promise. By partnering at the health system level rather than individual clinic level, Ochsner Health and Cognito are creating infrastructure to test how non-invasive neuromodulation works in real-world settings—generating the kind of practical, cost-focused data that health systems and insurance programs actually need to make coverage decisions. This article explores how this collaboration works, what Spectris technology involves, and what this partnership means for the broader landscape of Alzheimer’s treatment development and delivery.

How Health System Collaboration Accelerates Non-Invasive Alzheimer’s Innovation
Understanding Spectris Technology and How Non-Invasive Neuromodulation Works
Deploying Therapy Across Urban and Rural Populations
Building the Case for Cost-Effectiveness and Healthcare Integration
Non-Invasive Therapy and the Expanding Alzheimer’s Drug Pipeline
Medicare and Medicaid Coverage Pathways
The Future of Collaborative Care Models in Brain Health
Conclusion

How Health System Collaboration Accelerates Non-Invasive Alzheimer’s Innovation

The brain health Collaboratory represents a shift away from the traditional model where healthcare innovations reach patients slowly, if at all. Historically, a new Alzheimer’s therapy would be developed by a pharmaceutical or medical device company, go through clinical trials, receive FDA approval, and then hope that individual neurologists or geriatricians would adopt it. With 47 hospitals and hundreds of affiliated care sites already on board, Ochsner and Cognito have essentially built an instant network ready to enroll patients, track outcomes, and generate data at scale. This matters because Alzheimer’s affects nearly 7 million Americans, yet most don’t live near specialized memory disorder centers. A health system approach means rural patients in Louisiana and Mississippi can access the same therapy as those in urban centers like New Orleans.

What makes this collaboration particularly significant is the explicit focus on both urban and rural implementation. Healthcare systems often struggle with “last-mile” delivery—getting new treatments to distant clinics and home settings. The collaboratory is specifically designed to assess whether Spectris can work effectively when delivered across diverse geography, patient populations, and care settings. This isn’t a small clinical trial; it’s an operational proof-of-concept for how non-invasive Alzheimer’s therapy can become part of standard care rather than an experimental exception. The comparison is instructive: while most new Alzheimer’s treatments are tested in academic medical centers, the collaboratory is intentionally testing implementation in the messy, real-world conditions where most Americans actually receive care.

How Health System Collaboration Accelerates Non-Invasive Alzheimer's Innovation

Understanding Spectris Technology and How Non-Invasive Neuromodulation Works

Spectris is a non-invasive, at-home device that delivers synchronized light and sound stimulation through sensory pathways with the goal of promoting healthy neural network activity in the brain. The technology is based on research suggesting that specific patterns of sensory stimulation—particularly in the visual and auditory domains—can influence neural oscillations associated with memory and cognitive function. Patients wear the device at home, making it fundamentally different from therapies requiring frequent trips to a clinic or hospital for infusions or procedures.

Early evidence from preclinical studies and small clinical trials has shown that Spectris demonstrates potential in preserving brain structure and function in Alzheimer’s disease, which is notable because many Alzheimer’s drugs aim only to slow cognitive decline, not preserve actual brain tissue. However, there’s an important limitation: “promising” in early studies doesn’t automatically mean “effective for everyone.” The preclinical and early clinical data Spectris has shown are encouraging but still preliminary. The Brain Health Collaboratory is essentially the next phase of evidence-gathering, designed to answer questions the early research couldn’t: Does the benefit hold up when used at home, outside of a controlled research setting? Do patients stick with therapy (adherence is a major problem in chronic disease treatment)? Does it work equally well for people of different ages, backgrounds, and disease stages? These practical questions are why the health system partnership is essential—you can’t answer them with 50 patients in a university lab; you need hundreds across diverse populations.

Deploying Therapy Across Urban and Rural Populations

One of the collaboratory’s explicit goals is to assess how non-invasive Alzheimer’s therapy can be deployed at scale across diverse communities. This is more than logistics; it’s about health equity. Alzheimer’s disease disproportionately affects people with lower educational attainment and fewer economic resources, yet clinical trials and early access programs typically skew toward affluent populations near academic centers. By embedding Spectris deployment within Ochsner Health’s 47-hospital network, the collaboratory has immediate access to patient populations that represent real demographic and geographic diversity—urban patients, rural patients, people in safety-net hospitals, and communities that have historically been underrepresented in Alzheimer’s research.

Rural deployment presents specific challenges that the collaboratory will have to solve. In rural areas, specialist neurologists are scarce, so most Alzheimer’s diagnosis and ongoing care happens in primary care settings. Will Spectris work when prescribed by a general practitioner rather than a cognitive neurologist? Can remote support and telehealth bridge the gap if patients need troubleshooting? How do you handle device maintenance and replacement in communities with limited technical support? A real example: a 72-year-old in a small town in Mississippi can’t easily travel to Memphis for a clinical trial, but if her local Ochsner-affiliated clinic can screen her for candidacy, deliver a Spectris device, and provide support remotely, she suddenly has access to an innovation that would otherwise have required moving or months of travel. That’s the practical promise of this collaboration.

Deploying Therapy Across Urban and Rural Populations

Building the Case for Cost-Effectiveness and Healthcare Integration

The collaboratory will generate clinical and health economics data specifically designed to evaluate the cost-effectiveness of non-invasive neuromodulation therapies within value-based care models. This is a crucial detail because it means the partnership isn’t just tracking whether Spectris improves cognition; it’s tracking costs. Healthcare systems and insurance programs need to know the dollars-per-quality-adjusted-life-year (QALY) that Spectris delivers compared to standard care or other treatments. Is Spectris more cost-effective than cognitive behavioral therapy? Compared to drugs like lecanemab (which requires infusions)? Compared to doing nothing and just managing symptoms? This is where health system partnerships have a major advantage over traditional clinical trials.

Academic research programs typically don’t have the financial transparency that integrated healthcare systems do. Ochsner can track the full spectrum of costs: device cost, staff time for education and follow-up, emergency visits and hospitalizations that are prevented or delayed, and medication adjustments. By comparison, a standalone clinical trial might measure efficacy (did cognition improve) but miss real-world cost variation. If Spectris helps people stay independent longer, does that reduce the need for home health aides or nursing home placement? Those are expensive outcomes that health systems care about, and only a real-world implementation can measure them accurately.

Non-Invasive Therapy and the Expanding Alzheimer’s Drug Pipeline

The Brain Health Collaboratory operates within a broader landscape of rapidly accelerating Alzheimer’s treatment development. According to current tracking, there are 138 drugs in development for Alzheimer’s disease, assessed across 182 clinical trials globally. These candidates break down into distinct categories: 30% are biologically targeted therapies (like amyloid or tau modulators), 43% are small molecule drugs, 14% focus on cognitive enhancement, and 11% target neuropsychiatric symptoms like depression and anxiety. Spectris occupies a different category—it’s not a drug at all, but a device-based neuromodulation therapy. This positioning matters because it suggests the future of Alzheimer’s treatment will be multimodal: patients might eventually use a combination of targeted drugs (to address underlying pathology) plus supportive therapies like Spectris (to preserve function and quality of life).

However, the sheer number of drugs in development creates a challenge: the Alzheimer’s market could become crowded and competitive. Not every promising therapy will succeed, and many will fail to show benefit in larger trials or will be too expensive for widespread adoption. Non-invasive, home-based therapies like Spectris have inherent advantages in this competitive landscape. They don’t require monthly infusions or injections, they don’t have the side effect profiles of systemic drugs, and they can be used in combination with other treatments. A warning, though: the mere existence of many treatment options doesn’t mean they’re all accessible. Cost, insurance coverage, and healthcare infrastructure gaps will still limit who gets what therapy, which is precisely why the Davos Alzheimer’s Collaborative—which has committed over $700 million to accelerate drug development and transform healthcare system diagnosis and treatment approaches—is pushing for systemic change alongside scientific innovation.

Non-Invasive Therapy and the Expanding Alzheimer's Drug Pipeline

Medicare and Medicaid Coverage Pathways

The collaboratory is explicitly exploring integration of Spectris into programs serving dual-eligible Medicare and Medicaid populations. This is a specific, actionable goal: people who are eligible for both Medicare and Medicaid tend to be older, sicker, and poorer, and they represent a substantial portion of the Alzheimer’s population. However, getting Medicare and Medicaid coverage for a new device technology is complex. It requires evidence of effectiveness (which the collaboratory will generate), but also requires navigating reimbursement codes, setting appropriate payment rates, and ensuring that nursing homes and assisted living facilities can actually use the technology in their settings.

One practical challenge: many Alzheimer’s patients in the later stages live in long-term care facilities, not at home. For Spectris to have real-world impact at scale, facilities need to be able to integrate device use into daily routines, staff need training, and there need to be troubleshooting processes when devices malfunction. This is why pilot programs across 47 hospitals and affiliated care sites matter—they include long-term care facilities and home care providers in the testing, not just neurology clinics. The collaboratory isn’t just asking “does Spectris work” but “can a typical nursing home actually use this therapy with their existing staff and workflows?”.

The Future of Collaborative Care Models in Brain Health

The Brain Health Collaboratory signals a broader trend in how emerging Alzheimer’s therapies will reach patients in the future. Rather than waiting for academic centers to slowly publish papers over years, then waiting for individual clinicians to read those papers and adopt the therapy, health systems are now directly partnering with developers to implement innovation in real time. This model is likely to become more common as healthcare systems recognize that they have leverage—patient populations, data infrastructure, clinical workflows—that can accelerate the pathway from promising research to practical care. Looking ahead, we should expect more collaboratories.

Other health systems will likely develop similar partnerships with other neuromodulation companies, other pharmaceutical developers, or other non-invasive therapy innovators. The question is whether these partnerships will help close equity gaps or widen them. If health system partnerships remain concentrated in well-resourced systems like Ochsner, then innovation will still bypass rural and underserved urban communities. But if the model of “partner with health systems serving diverse populations and generate real-world evidence” becomes standard, then emerging Alzheimer’s therapies might finally reach the people who need them most, not just those lucky enough to live near a research center. The Brain Health Collaboratory’s explicit inclusion of rural communities suggests the latter may be possible—but only if other health systems and developers follow this example.

Conclusion

The Brain Health Collaboratory launched by Cognito Therapeutics and Ochsner Health represents a meaningful evolution in how healthcare systems can accelerate access to emerging Alzheimer’s therapies. By embedding non-invasive Spectris technology across 47 hospitals and hundreds of care sites—spanning both urban and rural populations—the partnership moves beyond traditional clinical trials to generate the real-world cost-effectiveness and implementation data that health systems actually need. This approach acknowledges a hard truth: developing a good therapy is not the same as getting it to patients, especially patients in communities with fewer resources.

If you or a family member is living with cognitive decline and interested in exploring non-invasive treatment options, having a conversation with your primary care doctor or local neurologist about Spectris and similar emerging therapies is a reasonable next step. As the collaboratory generates data over the coming months and years, availability and coverage will likely expand. For now, what matters is that a credible health system is betting that non-invasive neuromodulation has real potential—and is building the infrastructure to prove it at scale. That willingness to partner, invest, and deploy across diverse communities may ultimately matter more than the device itself.